References
- Adams, R. M. 1987. The Virtue of Faith and Other Essays in Philosophical Theology. New York: Oxford University Press.
- Amrhein, V., S. Greenland, and B. McShane. 2019. “Retire Statistical Significance.” Nature 567 (7748): 305–307. doi:https://doi.org/10.1038/d41586-019-00857-9.
- Anderson, E. E., and J. M. DuBois. 2012. “IRB Decision-making with Imperfect Knowledge: A Framework for Evidence-based Research Ethics Review.” Journal of Law, Medicine, and Ethics 40 (4): 951–969. doi:https://doi.org/10.1111/j.1748-720X.2012.00724.x.
- Appelbaum, P. S., L. H. Roth, C. W. Lidz, P. Benson, and W. Winslade. 1987. “False Hopes and Best Data: Consent to Research and the Therapeutic Misconception.” The Hastings Center Report 17 (2): 20–24. doi:https://doi.org/10.2307/3562038.
- Audi, R. 2005. The Good in the Right: A Theory of Intuition and Intrinsic Value. Princeton, NJ: Princeton University Press.
- Beauchamp, T. L., and J. F. Childress. 2012. Principles of Biomedical Ethics. 7th ed. New York: Oxford University Press.
- Brink, D. O. 1989. Moral Realism and the Foundations of Ethics. Cambridge, UK: Cambridge University Press.
- Burns, P. B., R. J. Rohrich, and K. C. Chung. 2011. “The Levels of Evidence and Their Role in Evidence-based Medicine.” Plastic and Reconstructive Surgery 128 (1): 305–310. doi:https://doi.org/10.1097/PRS.0b013e318219c171.
- Callaway, E. 2020. “Dozens to Be Deliberately Infected with Coronavirus in UK ‘Human Challenge’ Trials.” Nature 586 (7831): 651–652. doi:https://doi.org/10.1038/d41586-020-02821-4.
- Chisholm, R. M. 1989. Theory of Knowledge. 3rd ed. Englewood Cliffs, NJ: Prentice-Hall.
- Clapp, J. T., K. A. Gleason, and S. Joffe. 2017. “Justification and Authority in Institutional Review Board Decision Letters.” Social Science and Medicine 194: 25–33. doi:https://doi.org/10.1016/j.socscimed.2017.10.013.
- Copi, I., C. Cohen, and K. McMahon. 2013. Introduction to Logic. 14th ed. New York, NY: Routledge.
- Council for International Organizations of Medical Sciences. 2016. “International Ethical Guidelines for Health-related Research Involving Humans.” Accessed 17 June 2020. https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf
- Department of Health and Human Services. 2017. Protection of Human Subjects. 45 CFR 46.
- Douglas, H. 2000. “Inductive Risk and Values in Science.” Philosophy of Science 67 (4): 559–579. doi:https://doi.org/10.1086/392855.
- Dziak, K., R. Anderson, M. A. Sevick, C. S. Weisman, D. W. Levine, and S. H. Scholle. 2005. “Variations among Institutional Review Board Reviews in a Multisite Health Services Research Study.” Health Services Research 40 (1): 279–290. doi:https://doi.org/10.1111/j.1475-6773.2005.00353.x.
- Earman, J. 1992. Bayes or Bust? A Critical Examination of Bayesian Confirmation Theory. Cambridge, MA: MIT Press.
- Edwards, S. J. L., R. Ashcroft, and S. Kirchin. 2004. “Research Ethics Committees: Differences and Moral Judgment.” Bioethics 18 (5): 408–427. doi:https://doi.org/10.1111/j.1467-8519.2004.00407.x.
- Elliott, K. 2017. A Tapestry of Values: An Introduction to Values in Science. New York: Oxford University Press.
- Emanuel, E. J., D. Wendler, and C. Grady. 2000. “What Makes Clinical Research Ethical?” Journal of the American Medical Association 283 (20): 2701–2711. doi:https://doi.org/10.1001/jama.283.20.2701.
- Environmental Protection Agency. 2013. Protection of Human Subjects. 40 CFR 26.
- Eyal, N., M. Lipsitch, and P. G. Smith. 2020. “Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure.” The Journal of Infectious Diseases 11 (1): 1752–1756. doi:https://doi.org/10.1093/infdis/jiaa152.
- Food and Drug Administration. 2013. Institutional Review Boards. 21 CFR 56.
- Foot, P. 2001. Natural Goodness. Oxford, UK: Clarendon Press.
- Friedman, A., E. Robbins, and D. Wendler. 2012. “Which Benefits of Research Participation Count as ‘Direct’?” Bioethics 26 (2): 60–67. doi:https://doi.org/10.1111/j.1467-8519.2010.01825.x.
- Friesen, P., A. N. M. Yusof, and M. Sheehan. 2019. “Should the Decisions of Institutional Review Boards Be Consistent?” Ethics & Human Research 41 (4): 2–14. doi:https://doi.org/10.1002/eahr.500022.
- Gibbard, A. 1990. Wise Choices, Apt Feelings. Cambridge, MA: Harvard University Press.
- Giere, R. N., J. Bickle, and R. Mauldin. 2005. Understanding Scientific Reasoning. 5th ed. Belmont, CA: Cengage Learning.
- Goldman, A. 1986. Epistemology and Cognition. Cambridge, MA: Harvard University Press.
- Goldman, A. 2002. Knowledge in a Social World. Oxford, UK: Clarendon Press.
- Goldman, J., and M. D. Katz. 1982. “Inconsistency and Institutional Review Boards.” Journal of the American Medical Association 248 (2): 197–202. doi:https://doi.org/10.1001/jama.1982.03330020041027.
- Goozner, M. 2004. The $800 Million Pill. Berkeley, CA: University of California Press.
- Green, L. A., J. C. Lowery, C. P. Kowalski, and L. Wyszewianski. 2006. “Impact of Institutional Review Board Practice Variation on Observational Health Services Research.” Health Services Research 41 (1): 214–230. doi:https://doi.org/10.1111/j.1475-6773.2005.00458.x.
- Greene, J. 2013. Moral Tribes: Emotion, Reason, and the Gap between Us and Them. New York, NY: Penguin.
- Grinnell, F., J. Z. Sadler, V. McNamara, K. Senetar, and J. Reisch. 2017. “Confidence of IRB/REC Members in Their Assessments of Human Research Risk: A Study of IRB/REC Decision Making in Action.” Journal of Empirical Research in Human Research Ethics 12 (3): 140–149. doi:https://doi.org/10.1177/1556264617710386.
- Gunsalus, C. K., E. M. Bruner, N. C. Burbules, L. Dash, M. Finkin, J. P. Goldberg, W. T. Greenough, G. A. Miller, and M. G. Pratt. 2006. “Mission Creep in the IRB World.” Science 312 (5779): 1441. doi:https://doi.org/10.1126/science.1121479.
- Haack, S. 2003. Defending Science within Reason. New York, NY: Prometheus Books.
- Hannson, S. 2003. “Ethical Criteria of Risk Acceptance.” Erkenntnis 59 (3): 291–309. doi:https://doi.org/10.1023/A:1026005915919.
- Harman, G. 1996. “Moral Relativism.” In Moral Relativism and Moral Objectivity, edited by G. Harman and J. J. Thompson, 3–64. Cambridge MA: Blackwell Publishers.
- Hirshon, J. M., S. D. Krugman, M. D. Witting, J. P. Furuno, M. R. Limcangco, A. R. Perisse, and E. K. Rasch. 2002. “Variability in Institutional Review Board Assessment of Minimal-Risk Research.” Academic Emergency Medicine 9 (12): 1417–1420. doi:https://doi.org/10.1197/aemj.9.12.1417.
- Howson, C., and P. Urbach. 1989. Scientific Reasoning: A Bayesian Approach. New York, NY: Open Court.
- Jackson, F. 1998. From Metaphysics to Ethics: A Defence of Conceptual Analysis. Oxford, UK: Clarendon Press.
- Joffe, S., E. F. Cook, P. D. Cleary, J. W. Clark, and J. C. Weeks. 2001. “Quality of Informed Consent in Cancer Clinical Trials: A Cross-sectional Survey.” The Lancet 358 (9295): 1772–1777. doi:https://doi.org/10.1016/S0140-6736(01)06805-2.
- Kant, I. [1785] 1981. Groundwork for the Metaphysics of Morals. Ellington JW (transl.). Indianapolis, IN: Hackett.
- Katz, J. 1993. “Human Experimentation and Human Rights.” Saint Louis University Law Journal 38 (7): 7–54.
- Kimmelman, J. 2009. Gene Transfer and the Ethics of First-in-Human Research: Lost in Translation. Cambridge, UK: Cambridge University Press.
- King, N. 2000. “Defining and Describing Benefit Appropriately in Clinical Trials.” The Journal of Law, Medicine & Ethics 28 (4): 332–343. doi:https://doi.org/10.1111/j.1748-720X.2000.tb00685.x.
- Kitcher, P. 1993. The Advancement of Science. New York, NY: Oxford University Press.
- Klitzman, R. 2014. “How US Institutional Review Boards Decide When Researchers Need to Translate Studies.” Journal of Medical Ethics 40 (3): 193–197. doi:https://doi.org/10.1136/medethics-2012-101174.
- Klitzman, R. L. 2011a. “The Myth of Community Differences as the Cause of Variations among IRBs.” American Journal of Bioethics Primary Research 2 (2): 24–33.
- Klitzman, R. L. 2011b. “‘Members of the Same Club’: Challenges and Decisions Faced by US IRBs in Identifying and Managing Conflicts of Interest.” PLoS One 6 (7): e22796. doi:https://doi.org/10.1371/journal.pone.0022796.
- Klitzman, R. L. 2012a. “US IRBs Confronting Research in the Developing World.” Developing World Bioethics 12 (2): 63–73. doi:https://doi.org/10.1111/j.1471-8847.2012.00324.x.
- Klitzman, R. L. 2012b. “Institutional Review Board Community Members: Who are They, What Do They Do, and Whom Do They Represent?” Academic Medicine 87 (7): 975–981. doi:https://doi.org/10.1097/ACM.0b013e3182578b54.
- Klitzman, R. L. 2013a. “How IRBs View and Make Decisions about Coercion and Undue Influence.” Journal of Medical Ethics 39 (4): 224–229. doi:https://doi.org/10.1136/medethics-2011-100439.
- Klitzman, R. L. 2013b. “How IRBs View and Make Decisions about Consent Forms.” Journal of Empirical Research on Human Research Ethics 8 (1): 8–19. doi:https://doi.org/10.1525/jer.2013.8.1.8.
- Klitzman, R. L. 2013c. “How IRBs View and Make Decisions about Social Risks.” Journal of Empirical Research on Human Research Ethics 8 (3): 58–65. doi:https://doi.org/10.1525/jer.2013.8.3.58.
- Klitzman, R. L. 2013d. “How Good Does the Science Have to Be in Proposals Submitted to Institutional Review Boards? An Interview Study of Institutional Review Board Personnel.” Clinical Trials: Journal of the Society for Clinical Trials 10 (5): 761–766. doi:https://doi.org/10.1177/1740774513500080.
- Klitzman, R. L. 2015. The Ethics Police? The Struggle to Make Human Research Safe. New York, NY: Oxford University Press.
- Kon, A. A. 2009. “The Role of Empirical Research in Bioethics.” American Journal of Bioethics 9 (6–7): 59–65. doi:https://doi.org/10.1080/15265160902874320.
- Kuhn, T. S. 1977. The Essential Tension: Selected Studies in Scientific Tradition and Change. Chicago, IL: University of Chicago Press.
- Largent, E., and H. Fernandez Lynch. 2017. “Paying Research Participants: The Outsized Influence of ‘Undue Influence’.” IRB 39 (4): 1–9.
- Largent, E. A., C. Grady, F. G. Miller, and A. Wertheimer. 2012. “Money, Coercion, and Undue Inducement: Attitudes about Payments to Research Participants.” IRB 34 (1): 1–8.
- Lau, S., H. Luk, A. Wong, K. Li, L. Zhu, Z. He, J. Fung, T. T. Chan, K. S. Fung, and P. C. Woo. 2020. “Possible Bat Origin of Severe Acute Respiratory Syndrome Coronavirus 2.” Emerging Infectious Diseases 26 (7): 1542–1547. doi:https://doi.org/10.3201/eid2607.200092.
- Lenman, J. 2018. “Moral Naturalism.” Stanford Encyclopedia of Philosophy. Accessed 1 July 2020. https://plato.stanford.edu/entries/naturalism-moral/#WhatMoraNatu
- Levine, R. J. 1988. Ethics and Regulation of Clinical Research. New Haven, CT: Yale University Press.
- Loevinger, L. 1992. “Standards of Proof in Science and Law.” Jurimetrics 32 (3): 323–344.
- London, A. J. 2006. “Reasonable Risks in Clinical Research: A Critique and a Proposal for the Integrative Approach.” Statistics in Medicine 25 (17): 2869–2885. doi:https://doi.org/10.1002/sim.2634.
- McWilliams, R., J. Hoover-Fong, A. Hamosh, S. Beck, T. Beaty, and G. Cutting. 2003. “Problematic Variation in Local Institutional Review of a Multicenter Genetic Epidemiology Study.” Journal of the American Medical Association 290 (3): 360–366.
- Meslin, E. M. 1990. “Protecting Human Subjects from Harm through Improved Risk Judgments.” IRB: Ethics and Human Research 12 (1): 7–10. doi:https://doi.org/10.2307/3563683.
- Millum, J., and M. Garnett. 2019. “How Payment for Research Participation Can Be Coercive.” American Journal of Bioethics 19 (9): 21–31. doi:https://doi.org/10.1080/15265161.2019.1630497.
- Moon, M. R. 2009. “The History and Role of Institutional Review Boards: A Useful Tension.” Virtual Mentor 11 (4): 311–316.
- Moore, G. E. 1903. Principia Ethica. New York, NY: Cambridge University Press.
- National Commission for the Protection of Human Subjects of Biomedical or Behavioral Research. 1979. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC: Department of Health, Education, and Welfare.
- Northwestern University Institutional Review Board. 2020. “Templates and Forms.” Accessed 17 June 2020. https://www.irb.northwestern.edu/templates-forms-sops/
- Office of Science and Technology Policy. 2000. “Federal Research Misconduct Policy.” Federal Register 65 (235): 76260–76264.
- Oxford Centre for Evidence-Based Medicine, Levels of Evidence Working Group. 2011. “The 2011 Levels of Evidence.” Accessed 3 July 2020. http://www.cebm.net/index.aspx?o=5653
- Patashnik, E. M., A. S. Gerber, and C. M. Dowling. 2017. Unhealthy Politics: The Battle over Evidence-Based Medicine. Princeton, NJ: Princeton University Press.
- Petersen, L. A., K. Simpson, R. Sorelle, T. Urech, and S. S. Chitwood. 2012. “How Variability in the Institutional Review Board Review Process Affects Minimal-risk Multisite Health Services Research.” Annals of Internal Medicine 156 (10): 728–735. doi:https://doi.org/10.7326/0003-4819-156-10-201205150-00011.
- Porter, R. 1998. The Greatest Benefit to Mankind: A Medical History of Humanity. New York, NY: WW Norton.
- Pritchard, I. A. 2011. “How Do IRB Members Make Decisions? A Review and Research Agenda.” Journal of Empirical Research in Human Research Ethics 6 (2): 31–46. doi:https://doi.org/10.1525/jer.2011.6.2.31.
- Resnik, D. B. 2012. “Limits on Risks for Healthy Volunteers in Biomedical Research.” Theoretical Medicine and Bioethics 33 (2): 137–149. doi:https://doi.org/10.1007/s11017-011-9201-1.
- Resnik, D. B. 2014. “Consistency in IRB Review.” Journal of Clinical Research Best Practices 10 (12). Accessed 3 July 2020. http://www.firstclinical.com/journal/2014/1412_Consistency.pdf
- Resnik, D. B. 2017. “The Role of Intuition in Risk/benefit Decision-making in Human Subjects Research.” Accountability in Research 24 (1): 1–29. doi:https://doi.org/10.1080/08989621.2016.1198978.
- Resnik, D. B. 2018. The Ethics of Research with Human Subjects: Protecting People, Advancing Science, Promoting Trust. Cham, Switzerland: Springer.
- Resnik, D. B. 2019. “Coercion as Subjection and the Institutional Review Board.” The American Journal of Bioethics 19 (9): 56–58. doi:https://doi.org/10.1080/15265161.2019.1630499.
- Resnik, D. B., and R. R. Sharp. 2006. “Protecting Third Parties in Research.” IRB: Ethics & Human Research 28 (4): 1–7.
- Resnik, M. D. 2000. Mathematics as a Science of Patterns. New York, NY: Oxford University Press.
- Rid, A., E. J. Emanuel, and D. Wendler. 2010. “Evaluating the Risks of Clinical Research.” Journal of the American Medical Association 304 (13): 1472–1479. doi:https://doi.org/10.1001/jama.2010.1414.
- Ridge, M. 2019. “Moral Non-naturalism.” Stanford Encyclopedia of Philosophy. Accessed 2 July 2020. https://plato.stanford.edu/entries/moral-non-naturalism/#Int
- Rothstein, P., M. Rader, and D. Crump. 2011. Evidence. 6th ed. St. Paul, MN: West Publishing.
- Rudner, R. 1953. “The Scientist Qua Scientist Makes Value Judgments.” Philosophy of Science 20 (1): 1–6. doi:https://doi.org/10.1086/287231.
- Sackett, D. L. 1989. “Rules of Evidence and Clinical Recommendations on the Use of Antithrombotic Agents.” Chest 95 (2 Supplement): 2S–4S. doi:https://doi.org/10.1378/chest.95.2_Supplement.2S.
- Sackett, D. L., W. Richardson, W. Rosenberg, and R. Haynes. 2000. Evidence-Based Medicine: How to Practice and Teach EBM. 2nd ed. New York: Churchill Livingstone.
- Salje, H., C. Tran Kiem, N. Lefrancq, N. Courtejoie, P. Bosetti, J. Paireau, A. Andronico, N. Hozé, J. Richet, C. L. Dubost, et al. 2020. “Estimating the Burden of SARS-CoV-2 in France.” Science 369 (6500): 208–211. doi:https://doi.org/10.1126/science.abc3517.
- Schaefer, G. O., C. C. Tam, J. Savulescu, and T. C. Voo. 2020. “COVID-19 Vaccine Development: Time to Consider SARS-CoV-2 Challenge Studies?” Vaccine 38 (33): 5085–5088. doi:https://doi.org/10.1016/j.vaccine.2020.06.007.
- Schneider, C. E. 2015. The Censor’s Hand: The Misregulation of Human-subject Research. Cambridge, MA: MIT Press.
- Schrag, Z. M. 2010. Ethical Imperialism: Institutional Review Boards and the Social Sciences, 1965–2009. Baltimore, MD: Johns Hopkins University Press.
- Seiffert, D. 2016. “Report Suggests Drug-approval Rate Now Just 1-in-10.” Boston Business Journal, May 25. Accessed 26 May 2020. https://www.bizjournals.com/boston/blog/bioflash/2016/05/report-suggests-drug-approval-rate-now-just-1-in.html
- Selinger, E., and R. P. Crease, eds. 2006. The Philosophy of Expertise. New York, NY: Columbia University Press.
- Shah, S., A. Whittle, B. Wilfond, G. Gensler, and D. Wendler. 2004. “How Do Institutional Review Boards Apply the Federal Risk and Benefit Standards for Pediatric Research?” Journal of the American Medical Association 291 (4): 476–482. doi:https://doi.org/10.1001/jama.291.4.476.
- Shah, S. K., J. Kimmelman, A. D. Lyerly, H. F. Lynch, F. G. Miller, R. Palacios, C. A. Pardo, and C. Zorrilla. 2018. “Bystander Risk, Social Value, and Ethics of Human Research.” Science 360 (6385): 158–159. doi:https://doi.org/10.1126/science.aaq0917.
- Shah, S. K., F. G. Miller, T. C. Darton, D. Duenas, C. Emerson, H. F. Lynch, E. Jamrozik, N. S. Jecker, D. Kamuya, M. Kapulu, et al. 2020. “Ethics of Controlled Human Infection to Address COVID-19.” Science 368 (6493): 832–834. doi:https://doi.org/10.1126/science.abc1076.
- Shrader-Frechette, K. S. 1991. Risk and Rationality: Philosophical Foundations for Populist Reforms. Berkeley, CA: University of California Press.
- Silberman, G., and K. L. Kahn. 2011. “Burdens on Research Imposed by Institutional Review Boards: The State of the Evidence and Its Implications for Regulatory Reform.” Milbank Quarterly 89 (4): 599–627. doi:https://doi.org/10.1111/j.1468-0009.2011.00644.x.
- Spector, R. 2005. “Me Too Drugs.” Stanford Medicine Magazine, Summer. Accessed 26 May 2020. http://sm.stanford.edu/archive/stanmed/2005summer/drugs-metoo.html
- Stark, L. 2012. Behind Closed Doors: IRBs and the Making of Ethical Research. Chicago, IL: University of Chicago Press.
- Stiemsma, L. T., L. A. Reynolds, S. E. Turvey, and B. B. Finlay. 2015. “The Hygiene Hypothesis: Current Perspectives and Future Therapies.” ImmunoTargets and Therapy 4: 143–157. doi:https://doi.org/10.2147/ITT.S61528.
- Tait, R. C., J. T. Chibnall, A. Iltis, A. Wall, and T. L. Deshields. 2011. “Assessment of Consent Capability in Psychiatric and Medical Studies.” Journal of Empirical Research on Human Research Ethics 6 (1): 39–50. doi:https://doi.org/10.1525/jer.2011.6.1.39.
- Thagard, P. 1988. Computational Philosophy of Science. Cambridge, MA: MIT Press.
- Van Luijn, H. E., A. W. Musschenga, R. B. Keus, W. M. Robinson, and N. K. Aaronson. 2002. “Assessment of the Risk/benefit Ratio of Phase II Cancer Clinical Trials by Institutional Review Board (IRB) Members.” Annals of Oncology 13 (8): 1307–1313. doi:https://doi.org/10.1093/annonc/mdf209.
- Weijer, C. 2000. “The Ethical Analysis of Risk.” Journal of Law, Medicine and Ethics 28 (4): 344–361. doi:https://doi.org/10.1111/j.1748-720X.2000.tb00686.x.
- Weinstein, J. B., and I. Dewsbury. 2006. “Comment on the Meaning of ‘Proof beyond a Reasonable Doubt’.” Law, Probability and Risk 5 (2): 167–173. doi:https://doi.org/10.1093/lpr/mgl016.
- Weiss, P. A. 2011. Introductory Statistics. 9th ed. Upper Saddles River, NJ: Pearson.
- Wendler, D., L. Belsky, K. M. Thompson, and E. J. Emanuel. 2005. “Quantifying the Federal Minimal Risk Standard: Implications for Pediatric Research without a Prospect of Direct Benefit.” Journal of the American Medical Association 294 (7): 826–832. doi:https://doi.org/10.1001/jama.294.7.826.
- Wertheimer, A., and F. G. Miller. 2008. “Payment for Research Participation: A Coercive Offer?” Journal of Medical Ethics 34 (5): 389–392. doi:https://doi.org/10.1136/jme.2007.021857.
- World Health Organization. 2020. “Key Criteria for the Ethical Acceptability of COVID-19 Human Challenge Studies.” Accessed 27 May 2020. https://apps.who.int/iris/bitstream/handle/10665/331976/WHO-2019-nCoV-Ethics_criteria-2020.1-eng.pdf?ua=1